Haemonetics Corporation Stock 12‑Month Price Target Raised to $115.5, Implies 14% Upside
Haemonetics Corporation's average stock price target increased from $113.5 to $115.5, with a range of $86 to $140, according to 10 analysts. This implies a 14% upside from the Oct. 7 closing price. The consensus rating remains 'Buy' among 12 analysts, with 9 Buys and 3 Holds.
How this was made
The 30-second read
Why it matters
The upward revision signals improved outlook but lacks concrete operational catalysts.
Market read
Analyst target raise offers modest upside potential for HAEM.
What to watch
No new operational data; price target change alone may not sustain a rally.
Background
Analyst consensus remains a Buy with 9 Buys and 3 Holds.
Market effects
May lift sentiment for medical device sector peers.
Limited to US-listed healthcare stocks.
Minimal global impact.
Counterpoint
Target raise could be premature if upcoming earnings miss expectations.
Key entities
- companyHaemonetics Corporation
Medical device manufacturer
